Pages that link to "Q60325744"
Jump to navigation
Jump to search
The following pages link to Peter C. Taylor (Q60325744):
Displaying 23 items.
- Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis (Q30832987) (← links)
- Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial (Q35540009) (← links)
- Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis (Q39278798) (← links)
- Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease (Q40433213) (← links)
- Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or (Q64101588) (← links)
- Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis (Q64102958) (← links)
- How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. (Q64927637) (← links)
- Human neutrophils secrete vascular endothelial growth factor (Q73721703) (← links)
- Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab (Q82534227) (← links)
- Developing anti-TNF and biologic agents (Q84540134) (← links)
- Recent evidence for the achievement of remission in rheumatoid arthritis through early aggressive therapy (Q84600198) (← links)
- Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making (Q89536784) (← links)
- The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies (Q90251931) (← links)
- Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial (Q90281755) (← links)
- Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohor (Q90465520) (← links)
- Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis (Q91650508) (← links)
- Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients (Q92414533) (← links)
- Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study (Q92607395) (← links)
- Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial (Q92854346) (← links)
- Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM (Q93156337) (← links)
- Adopting PROs in virtual and outpatient management of RA (Q96172128) (← links)
- A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 (Q114220831) (← links)
- The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies (Preprint) (Q124701408) (← links)